Can you please explain "patient enrolment timing because of funding issues (the Eastern Capital backed loan & Hepalink stepping up in a big way)".  

Michael Sweeney had been giving out various patient enrollment data/dates and the last one he gave was 2425 as of March 18 2018.  So what do we make of these data points given out by Sweeney?

And the fact that the published report a few weeks back stated "2700 patient years on Apabetalone", which backs out to 2400 on Phase 3 dosed patient years...implying 4800+ patient years for the trial, muddies the picture ever so much.